

Marjatta Leirisalo-Repo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3146609/publications.pdf>

Version: 2024-02-01

83
papers

3,025
citations

196777

29
h-index

182931

54
g-index

85
all docs

85
docs citations

85
times ranked

2899
citing authors

#	ARTICLE	IF	CITATIONS
1	Pretreatment resistin levels are associated with erosive disease in early rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs and infliximab. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 180-185.	0.6	7
2	Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis. <i>Rheumatology International</i> , 2022, 42, 1015-1025.	1.5	3
3	Induction of remission in female rheumatoid arthritis patients is associated with stabilization of myocardial abnormalities: a prospective cardiac magnetic resonance follow-up study. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 104-112.	0.6	1
4	AB0250...TOFACITINIB SUPPRESSES SEVERAL JAK-STAT PATHWAYS IN RHEUMATOID ARTHRITIS AND BASELINE SIGNALING PROFILE ASSOCIATES WITH TREATMENT RESPONSE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1150.2-1151.	0.5	0
5	Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response. <i>Frontiers in Immunology</i> , 2021, 12, 738481.	2.2	23
6	Rheumatoid arthritis patients with predominantly tender joints rarely achieve clinical remission despite being in ultrasound remission. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab030.	0.3	5
7	Myocardial changes detected with modern cardiac magnetic resonance techniques in patients with early rheumatoid arthritis. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, .	0.5	0
8	Major reduction of ultrasound-detected synovitis during subcutaneous tocilizumab treatment: results from a multicentre 24 week study of patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 262-270.	0.6	8
9	Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study. <i>Journal of Rheumatology</i> , 2020, 47, 1160-1164.	1.0	12
10	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. <i>Frontiers in Immunology</i> , 2020, 11, 578848.	2.2	11
11	Reactive arthritis and other musculoskeletal symptoms associated with acquisition of diarrhoeagenic <i>Escherichia coli</i> (DEC). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 605-611.	0.5	12
12	Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial. <i>Arthritis Care and Research</i> , 2019, 71, 1450-1458.	1.5	4
13	Inflammatory biomarkers in saliva and serum of patients with rheumatoid arthritis with respect to periodontal status. <i>Annals of Medicine</i> , 2018, 50, 333-344.	1.5	26
14	High burden of adverse events is associated with reduced remission rates in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 1689-1694.	1.0	8
15	One-Year Follow-up Study Detects Myocardial Changes with Cardiovascular Magnetic Resonance Tagging in Active Rheumatoid Arthritis. <i>Academic Radiology</i> , 2018, 25, 476-485.	1.3	7
16	Somatic <i>STAT3</i> mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia. <i>Haematologica</i> , 2018, 103, 304-312.	1.7	50
17	Anti-rheumatic medication and salivary MMP-8, a biomarker for periodontal disease. <i>Oral Diseases</i> , 2018, 24, 1562-1571.	1.5	17
18	Activity of rheumatoid arthritis correlates with oral inflammatory burden. <i>Rheumatology International</i> , 2018, 38, 1661-1669.	1.5	11

#	ARTICLE	IF	CITATIONS
19	Clonal hematopoiesis in patients with rheumatoid arthritis. <i>Blood Cancer Journal</i> , 2018, 8, 69.	2.8	62
20	THU0200â€¦Subcutaneous tocilizumab in patients with rheumatoid arthritis; a high number of patients achieve doppler remission after 24 weeks. , 2018, , .		0
21	Serum Epstein-Barr virus DNA, detected by droplet digital PCR, correlates with disease activity in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 778-784.	0.4	5
22	Periodontitis in early and chronic rheumatoid arthritis: a prospective follow-up study in Finnish population. <i>BMJ Open</i> , 2017, 7, e011916.	0.8	61
23	Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 75.	1.6	13
24	Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. <i>Nature Communications</i> , 2017, 8, 15869.	5.8	83
25	Patient-reported outcomes as predictors of remission in early rheumatoid arthritis patients treated with tight control treat-to-target approach. <i>Rheumatology International</i> , 2017, 37, 825-830.	1.5	9
26	Impaired Akt Phosphorylation in Monocytes of Patients with Rheumatoid Arthritis. <i>Scandinavian Journal of Immunology</i> , 2017, 85, 155-161.	1.3	7
27	<i>Yersinia enterocolitica</i> biotype 1A: a possible new trigger of reactive arthritis. <i>Rheumatology International</i> , 2017, 37, 1863-1869.	1.5	16
28	The effect of cryotherapy on total antioxidative capacity in patients with active seropositive rheumatoid arthritis. <i>Rheumatology International</i> , 2017, 37, 1481-1487.	1.5	29
29	OP0024â€¦Drug trough levels and antidrug antibodies in nonselected ankylosing spondylitis patients using self-injected antitnf drugs. , 2017, , .		0
30	Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. <i>PLoS ONE</i> , 2017, 12, e0183294.	1.1	30
31	STAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0167975.	1.1	15
32	A6.02â€¦Somatic mutations in clonally expanded CD8⁺T cells in patients with newly diagnosed rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A47.2-A48.	0.5	0
33	Renal diseases in patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 432-433.	0.6	3
34	Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 52-58.	0.5	111
35	Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 184-90.	0.4	3
36	Cardiac magnetic resonance imaging reveals frequent myocardial involvement and dysfunction in active rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 416-23.	0.4	13

#	ARTICLE	IF	CITATIONS
37	Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1038-1044.	0.4	5
38	Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1065-1071.	0.4	5
39	AB0362â€¦Depressive Symptoms and the Risk of Work Disability in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1014.2-1014.	0.5	0
40	THU0119â€¦Impact of Neglecting Intra-Articular Glucocorticoid-Injections in Remission Targeted Treatment of Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 237.2-237.	0.5	2
41	Constitutive STAT3 Phosphorylation in Circulating CD4+ T Lymphocytes Associates with Disease Activity and Treatment Response in Recent-Onset Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0137385.	1.1	24
42	Impact of rheumatic diseases on oral health and quality of life. <i>Oral Diseases</i> , 2015, 21, 342-348.	1.5	35
43	AB0373â€¦Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 928-928.	0.5	1
44	Failure in Longterm Treatment is Rare in Actively Treated Patients with Rheumatoid Arthritis, But May Be Predicted by High Health Assessment Score at Baseline and by Residual Disease Activity at 3 and 6 Months: The 5-year Followup Results of the Randomized Clinical NEO-RACo Trial. <i>Journal of Rheumatology</i> , 2014, 41, 2379-2385.	1.0	6
45	Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1954-1961.	0.5	40
46	FRI0254â€¦Predictive Value of Pretreatment Resistin Levels for Erosive Disease in Early RA Treated with DMARDs and Infliximab. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 475.2-475.	0.5	0
47	What is the best treatment strategy for early RA?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 523-536.	1.4	11
48	A Review of Serological Tests to Assist Diagnosis of Reactive Arthritis: Critical Appraisal on Methodologies. <i>Frontiers in Immunology</i> , 2013, 4, 418.	2.2	20
49	Infliximab for 6â€¦months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo) Tj ETQq1 1 0.784314 rgB76 Overlo	0.5	0
50	FRI0092â€¦Disease activity at three months is an excellent predictor of long-term treatment failure in actively treated rheumatoid arthritis patients, 5-year results of the neo-raco trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A400.2-A401.	0.5	0
51	FRI0185â€¦In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept at 50 mg or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-arm, double-blind study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A434.3-A435.	0.5	4
52	THU0178â€¦Comprehensive Disease Control with Golimumab in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A223.3-A224.	0.5	3
53	Rheumatoid Atlantoaxial Subluxation Can Be Prevented by Intensive Use of Traditional Disease Modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2009, 36, 273-278.	1.0	50
54	Effectiveness of different cryotherapies on pain and disease activity in active rheumatoid arthritis. A randomised single blinded controlled trial. <i>Clinical and Experimental Rheumatology</i> , 2006, 24, 295-301.	0.4	48

#	ARTICLE	IF	CITATIONS
55	Early arthritis and infection. <i>Current Opinion in Rheumatology</i> , 2005, 17, 433-439.	2.0	39
56	Reactive arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2005, 34, 251-259.	0.6	87
57	Microbial factors in spondyloarthropathies: insights from population studies. <i>Current Opinion in Rheumatology</i> , 2003, 15, 408-412.	2.0	40
58	Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. <i>Rheumatology International</i> , 2001, 20, 192-196.	1.5	62
59	IL10.G microsatellites mark promoter haplotypes associated with protection against the development of reactive arthritis in Finnish patients. <i>Arthritis and Rheumatism</i> , 2001, 44, 1209-1214.	6.7	59
60	Antineutrophil cytoplasmic antibodies in patients with early rheumatoid arthritis: An early marker of progressive erosive disease. <i>Arthritis and Rheumatism</i> , 2000, 43, 1371-1377.	6.7	49
61	Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations. <i>Arthritis and Rheumatism</i> , 2000, 43, 2397-2401.	6.7	93
62	Agalactosyl IgG is elevated in patients with active spondyloarthropathy. <i>Rheumatology International</i> , 1999, 18, 171-176.	1.5	30
63	Salmonella-triggered reactive arthritis: Use of polymerase chain reaction, immunocytochemical staining, and gas chromatography-mass spectrometry in the detection of bacterial components from synovial fluid. <i>Arthritis and Rheumatism</i> , 1999, 42, 84-89.	6.7	77
64	Systemic inflammatory response syndrome without systemic inflammation in acutely ill patients admitted to hospital in a medical emergency. <i>Clinical Science</i> , 1999, 96, 287-295.	1.8	24
65	Therapeutic Aspects of Spondyloarthropathies - A Review. <i>Scandinavian Journal of Rheumatology</i> , 1998, 27, 323-328.	0.6	18
66	Long term prognosis of reactive salmonella arthritis. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 516-520.	0.5	96
67	The Significance of Serum Anti-Borrelia Antibodies in the Diagnostic Work-Up of Uveitis. <i>European Journal of Ophthalmology</i> , 1997, 7, 251-255.	0.7	16
68	Progression of cervical spine changes in patients with early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 1997, 24, 1280-4.	1.0	83
69	Time Course of β_2 -Integrin CD11b/CD18 (Mac-1, $\alpha_M\beta_2$) Upregulation on Neutrophils and Monocytes after Coronary Artery Bypass Grafting: CD11b upregulation after CABG surgery. <i>Scandinavian Journal of Thoracic and Cardiovascular Surgery</i> , 1996, 30, 141-148.	0.2	21
70	Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. <i>Arthritis and Rheumatism</i> , 1996, 39, 996-1005.	6.7	67
71	Sulfasalazine in the treatment of spondylarthropathy. <i>Arthritis and Rheumatism</i> , 1995, 38, 618-627.	6.7	378
72	High Frequency of Silent Inflammatory Bowel Disease in Spondylarthropathy. <i>Arthritis and Rheumatism</i> , 1994, 37, 23-31.	6.7	196

#	ARTICLE	IF	CITATIONS
73	Different DRB1*04 alleles predominate in the Finnish random population and in HLA-B*27-positive subpopulations. <i>Tissue Antigens</i> , 1994, 44, 329-331.	1.0	9
74	The Present Knowledge of the Inflammatory Process and the Inflammatory Mediators. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1994, 75, 1-3.	0.0	44
75	Are antibiotics of any use in reactive arthritis?. <i>Apmis</i> , 1993, 101, 575-581.	0.9	32
76	Gut and spondyloarthropathies. <i>Rheumatic Disease Clinics of North America</i> , 1992, 18, 23-35.	0.8	3
77	Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to <i>Chlamydia</i> arthritis. <i>Arthritis and Rheumatism</i> , 1991, 34, 6-14.	6.7	273
78	Serum hyaluronate level as a predictor of radiologic progression in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1991, 34, 815-821.	6.7	74
79	Chemotaxis and chemiluminescence responses of synovial fluid polymorphonuclear leucocytes during acute reactive arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1990, 49, 615-619.	0.5	10
80	Enhanced Inflammatory Reactivity in the Pathogenesis of Spondyloarthropathies. <i>Autoimmunity</i> , 1990, 7, 245-254.	1.2	8
81	Platelet autoantibodies detected by immunoblotting in systemic lupus erythematosus: Association with the lupus anticoagulant, and with history of thrombosis and thrombocytopenia. <i>European Journal of Haematology</i> , 1990, 44, 234-239.	1.1	24
82	Ten-year followup study of patients with <i>Yersinia</i> arthritis. <i>Arthritis and Rheumatism</i> , 1988, 31, 533-537.	6.7	111
83	ANTI-DNA ANTIBODIES: THE CHOICE OF ASSAYS FOR ROUTINE DIAGNOSTIC WORK. <i>Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section C, Immunology</i> , 1985, 93C, 13-18.	0.2	5